Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease

Journal of Hepatology

Volumn 67, Issue 3, 2017, Pages 490-500

  Tan Garcia, Alfonso ^a   Wai, Lu En ^b   Zheng, Dahai ^c   Ceccarello, Erica ^c,d   Jo, Juandy ^b   Banu, Nasirah ^a   Khakpoor, Atefeh ^a   Chia, Adeline ^a   Tham, Christine Y L ^a   Tan, Anthony T ^a   Hong, Michelle ^a   Keng, Choong Tat ^c   Rivino, Laura ^a   Tan, Kai Chah ^e   Lee, Kang Hoe ^e   Lim, Seng Gee ^d,f   Newell, Evan W ^g   Pavelka, Norman ^g   Chen, Jinmiao ^g   Ginhoux, Florent ^a,g   Chen, Qingfeng ^c,h   Bertoletti, Antonio ^a,b,g   Dutertre, Charles Antoine ^a,g   more..

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e GLENEAGLES HOSPITAL   (Singapore)

^f NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^g AGENCY FOR SCIENCE   (Singapore)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Bacterial translocation; Endotoxin tolerance; Liver inflammation; Monocyte macrophage; Viral hepatitis

Indexed keywords

ANTIBIOTIC AGENT; CD14 ANTIGEN; ENDOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; CELL SURFACE RECEPTOR; LECTIN; LIPOPOLYSACCHARIDE RECEPTOR; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CD206+ MACROPHAGE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DELTA AGENT HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; INTESTINE FLORA; LIVER CIRRHOSIS; MACROPHAGE; MOUSE; MOUSE MODEL; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; PHYSIOLOGY; VIRUS HEPATITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; GASTROINTESTINAL MICROBIOME; HEPATITIS, VIRAL, HUMAN; HLA-DR ANTIGENS; HUMANS; LECTINS, C-TYPE; LIPOPOLYSACCHARIDE RECEPTORS; MACROPHAGES; MANNOSE-BINDING LECTINS; MICE; MYELOID CELLS; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020908446     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.04.023     Document Type: Article

References (53)

1. El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273 e1261.
2. Guidotti, L.G., Chisari, F.V., Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 (2006), 23–61.
3. Gehring, A.J., Ho, Z.Z., Tan, A.T., Aung, M.O., Lee, K.H., Tan, K.C., et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137 (2009), 682–690.
4. Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81 (2007), 4215–4225.
5. Wedemeyer, H., He, X.S., Nascimbeni, M., Davis, A.R., Greenberg, H.B., Hoofnagle, J.H., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 (2002), 3447–3458.
6. Maini, M.K., Boni, C., Lee, C.K., Larrubia, J.R., Reignat, S., Ogg, G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000), 1269–1280.
7. Bowen, D.G., Walker, C.M., Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005), 946–952.
8. Knolle, P.A., Thimme, R., Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146 (2014), 1193–1207.
9. Liaskou, E., Zimmermann, H.W., Li, K.K., Oo, Y.H., Suresh, S., Stamataki, Z., et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology 57 (2013), 385–398.
10. Zimmermann, H.W., Seidler, S., Nattermann, J., Gassler, N., Hellerbrand, C., Zernecke, A., et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One, 5, 2010 e11049.
11. Zhang, J.Y., Zou, Z.S., Huang, A., Zhang, Z., Fu, J.L., Xu, X.S., et al. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS One, 6, 2011 e17484.
12. Bility, M.T., Cheng, L., Zhang, Z., Luan, Y., Li, F., Chi, L., et al. Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages. PLoS Pathog, 10, 2014 e1004032.
13. McGuinness, P.H., Painter, D., Davies, S., McCaughan, G.W., Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46 (2000), 260–269.
14. Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Mockel, D., et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63 (2014), 1960–1971.
15. Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 59 (2014), 1060–1072.
16. Tacke, F., Zimmermann, H.W., Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60 (2014), 1090–1096.
17. Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 60 (2014), 1310–1324.
18. Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13 (2007), 1324–1332.
19. Dapito, D.H., Mencin, A., Gwak, G.Y., Pradere, J.P., Jang, M.K., Mederacke, I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
20. Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
21. Jo, J., Tan, A.T., Ussher, J.E., Sandalova, E., Tang, X.Z., Tan-Garcia, A., et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog, 10, 2014 e1004210.
22. Dutertre, C.A., Amraoui, S., DeRosa, A., Jourdain, J.P., Vimeux, L., Goguet, M., et al. Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNFalpha overproduction in response to microbial products. Blood 120 (2012), 2259–2268.
23. Guilliams, M., Dutertre, C.A., Scott, C.L., McGovern, N., Sichien, D., Chakarov, S., et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45 (2016), 669–684.
24. Becher, B., Schlitzer, A., Chen, J., Mair, F., Sumatoh, H.R., Teng, K.W., et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol 15 (2014), 1181–1189.
25. Cheng, Y., Wong, M.T., van der Maaten, L., Newell, E.W., Categorical analysis of human T cell heterogeneity with one-dimensional soli-expression by nonlinear stochastic embedding. J Immunol 196 (2016), 924–932.
26. Keng, C.T., Sze, C.W., Zheng, D., Zheng, Z., Yong, K.S., Tan, S.Q., et al. Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection. Gut, 2015.
27. Tang, X.Z., Jo, J., Tan, A.T., Sandalova, E., Chia, A., Tan, K.C., et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 190 (2013), 3142–3152.
28. Tu, Z., Bozorgzadeh, A., Crispe, I.N., Orloff, M.S., The activation state of human intrahepatic lymphocytes. Clin Exp Immunol 149 (2007), 186–193.
29. Lin, R.S., Lee, F.Y., Lee, S.D., Tsai, Y.T., Lin, H.C., Lu, R.H., et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 22 (1995), 165–172.
30. Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir el, A.D., Tadmor, M.D., et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162 (2015), 184–197.
31. Wiest, R., Lawson, M., Geuking, M., Pathological bacterial translocation in liver cirrhosis. J Hepatol 60 (2014), 197–209.
32. Ding, W.X., Jaeschke, H., Autophagy in macrophages regulates the inflammasome and protects against liver injury. J Hepatol 64 (2016), 16–18.
33. Nguyen, N.T., Hanieh, H., Nakahama, T., Kishimoto, T., The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 25 (2013), 335–343.
34. Dobrovolskaia, M.A., Vogel, S.N., Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 4 (2002), 903–914.
35. Adib-Conquy, M., Cavaillon, J.M., Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J Biol Chem 277 (2002), 27927–27934.
36. Sandler, N.G., Koh, C., Roque, A., Eccleston, J.L., Siegel, R.B., Demino, M., et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141 (2011), 1220–1230 e1221–e1223.
37. Balmer, M.L., Slack, E., de Gottardi, A., Lawson, M.A., Hapfelmeier, S., Miele, L., et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med, 6, 2014, 237ra266.
38. Sitia, G., Iannacone, M., Aiolfi, R., Isogawa, M., van Rooijen, N., Scozzesi, C., et al. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog, 7, 2011 e1002061.
39. Heymann, F., Peusquens, J., Ludwig-Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62 (2015), 279–291.
40. Ginhoux, F., Schultze, J.L., Murray, P.J., Ochando, J., Biswas, S.K., New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol 17 (2016), 34–40.
41. Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159 (2014), 1312–1326.
42. Shalova, I.N., Lim, J.Y., Chittezhath, M., Zinkernagel, A.S., Beasley, F., Hernandez-Jimenez, E., et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha. Immunity 42 (2015), 484–498.
43. Biswas, S.K., Lopez-Collazo, E., Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30 (2009), 475–487.
44. Sato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42 (2015), 123–132.
45. Hosel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50 (2009), 1773–1782.
46. Kennedy, P.T., Sandalova, E., Jo, J., Gill, U., Ushiro-Lumb, I., Tan, A.T., et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143 (2012), 637–645.
47. Chen, Y., Qin, N., Guo, J., Qian, G., Fang, D., Shi, D., et al. Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics, 15, 2014, 753.
48. Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
49. Bertoletti, A., Kennedy, P.T., The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 12 (2015), 258–263.
50. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
51. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
52. Bajaj, J.S., Sterling, R.K., Betrapally, N.S., Nixon, D.E., Fuchs, M., Daita, K., et al. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther 44 (2016), 638–643.
53. Kalambokis, G.N., Tsianos, E.V., Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55 (2012), 655–656.